Skip to main content

Topic

Biosimilars

856 published works

  1. Big Molecule Watch

    FDA Accepts Dr. Reddy’s Laboratories’ BLA for Abatacept Biosimilar

    By Emma Murray

    Dr. Reddy’s Laboratories (“Dr. Reddy’s”) announced on February 22 that the FDA accepted its BLA for DRL_AB, a proposed interchangeable biosimilar to Bristol-Myers Squibb’s ORENCIA® (abatacept) IV for infusion. According…

  2. Big Molecule Watch

    Janssen Files BPCIA Complaint Against Bio-Thera and Accord Related to Golimumab Biosimilar

    By Christopher Cassella|Kevin DeJong

    On March 3, Janssen Biotech, Inc. and Janssen Sciences Ireland UC (collectively, “Janssen”) filed a BPCIA complaint in the U.S. District Court for the District of Delaware against Accord BioPharma,…

  3. Biosimilars Law Bulletin

    ITC as a Biosimilar Battleground: Genentech Challenges Biocon’s Pertuzumab Biosimilar

    By Sheena Wang, Jennifer P. Nock

    On February 27, 2026, Genentech filed a complaint at the U.S. International Trade Commission (ITC) alleging that Biocon’s importation of its pertuzumab biosimilar, BMAB 1500/PERT-IJS (“BMAB 1500”), violates 19 U.S.C.…

  4. Big Molecule Watch

    Genentech Brings Pertuzumab Biosimilar Fight to the ITC

    By Natasha Daughtrey|Kevin DeJong|Christopher Cassella

    On February 27, 2026, Genentech filed a Section 337 complaint at the U.S. International Trade Commission (ITC) targeting Biocon’s proposed pertuzumab biosimilar, BMAB 1500/PERT-IJS, which references Genentech’s PERJETA®.  The complaint,…

  5. Big Molecule Watch

    European Biosimilar Updates

    By Allegra Padula

    On February 13, 2026, STADA and Bio-Thera announced that they have received European Marketing Authorization for GOTENFIA®, a golimumab biosimilar to Johnson & Johnson’s SIMPONI®.  GOTENFIA® is a human monoclonal…

  6. Big Molecule Watch

    FDA Approves Accord’s FILKRI (filgrastim-laha), a Biosimilar to NEUPOGEN

    By Yoko Bian

    On February 17, 2026, the U.S. Food and Drug Administration (FDA) approved FILKRI (filgrastim-laha), a biosimilar to Amgen’s NEUPOGEN (filgrastim).  FILKRI was developed by Accord BioPharma, the U.S. specialty division…

  7. Big Molecule Watch

    Formycon and Lotus Expand Collaboration in Asia-Pacific Region to Pembrolizumab Biosimilar

    By Harrison Gunn

    On February 11, 2026, Formycon AG and Lotus Pharmaceutical announced the execution of an exclusive license agreement directed to Formycon’s pembrolizumab biosimilar candidate, FYB206.  Pembrolizumab is currently approved as KEYTRUDA…

  8. Spicy IP

    ER Squibb to map Zydus’s product: Does this mean closure?

    By Yogesh Byadwal

    There has been another development in ER Squibb v Zydus, at the center of which is Nivolumab, an anti-cancer drug. Readers will remember that on 12th January 2025, a division bench of…

  9. Big Molecule Watch

    Samsung and Regeneron Settle Aflibercept BPCIA Case

    By Riley Wyberg

    On February 11, 2026, Samsung Bioepis, Co., Ltd (“Samsung”) and Regeneron Pharmaceuticals, Inc. (“Regeneron”) filed a Joint Stipulation and Proposed Order seeking to dismiss all claims and counterclaims without prejudice…

  10. Big Molecule Watch

    Hikma Launches Denosumab Biosimilars ENOBY and XTRENBO

    By Christopher Cassella

    On January 19, 2026, Hikma announced the U.S. launch of ENOBY (denosumab-qbde) and XTRENBO (denosumab-qbde)—denosumab biosimilars referencing Amgen’s PROLIA and XGEVA, respectively.  As recited in the announcement, “[d]enosumab is indicated for treating osteoporosis in…